about
New concepts of resistance in the treatment of Helicobacter pylori infectionsThe antibacterial effect of fatty acids on Helicobacter pylori infectionSecond and third line treatment options for Helicobacter pylori eradicationThe diagnosis and treatment of Helicobacter pylori infection in Arctic regions with a high prevalence of infection: Expert CommentaryCharacterization and inactivation of an agmatine deiminase from Helicobacter pyloriCategorization of upper gastrointestinal symptoms is useful in predicting background factors and studying effects and usages of digestive drugsThe clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradicationContemporary Diagnostic Strategies for the Detection of Helicobacter pylori InfectionDual-priming oligonucleotide-based multiplex PCR using tissue samples in rapid urease test in the detection of Helicobacter pylori infection.Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection.Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradicationDiscovery of novel mutations for clarithromycin resistance in Helicobacter pylori by using next-generation sequencingCost-effectiveness of six strategies for Helicobacter pylori diagnosis and management in uninvestigated dyspepsia assuming a high resource intensity practice pattern.Update on the first-line treatment for Helicobacter pylori infection - a continuing challenge from an old enemy.Genotypic resistance in Helicobacter pylori strains correlates with susceptibility test and treatment outcomes after levofloxacin- and clarithromycin-based therapies.Helicobacter pylori research: historical insights and future directions.Multicenter survey of routine determinations of resistance of Helicobacter pylori to antimicrobials over the last 20 years (1990 to 2009) in Belgium.Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?Helicobacter pylori infection: is sequential therapy superior to standard triple therapy? A single-centre Italian study in treatment-naive and non-treatment-naive patients.Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development.Effectiveness of ranitidine bismuth citrate and proton pump inhibitor based triple therapies of Helicobacter pylori in Turkey.The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study.Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran.Sequential Therapy is Superior to Triple Therapy for Helicobacter pylori Infection in Children: A Meta-Analysis.Comparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese PopulationEpidemiological aspects of gastric adenocarcinoma: are predictive diagnostics and targeted preventive measures possible?Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line.The incidence of primary antibiotic resistance of Helicobacter pylori in VietnamValidation of a fluorescence in situ hybridization method using peptide nucleic acid probes for detection of Helicobacter pylori clarithromycin resistance in gastric biopsy specimens.Antibiotics resistance rate of Helicobacter pylori in BhutanTailored Therapy Versus Empiric Chosen Treatment for Helicobacter pylori Eradication: A Meta-AnalysisInflammation and foveolar hyperplasia are reduced by supplemental dietary glutamine during Helicobacter pylori infection in mice.Complete Genome Sequences of Helicobacter pylori Clarithromycin-Resistant Strains.Review article: the global emergence of Helicobacter pylori antibiotic resistance.Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer diseaseDevelopment of vaccines against Helicobacter pylori.Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication.Evidence-based approach to dyspepsia: from Helicobacter pylori to functional disease.
P2860
Q24622513-52D2B9AE-2A30-4776-808A-6D93D1C75139Q26771996-69AB355B-7EBC-40CA-9B3D-1AE138294D66Q26829666-CEEDFED9-C255-40FC-A2CC-8EA5CCB272C4Q26852409-20C6A931-BBE4-4968-B6C8-EC9914E9F32BQ27658787-9390473A-3088-4812-9E38-0358B72E1067Q28539552-B5390D6B-72D0-4E56-96FC-61CA3B7B87DBQ28542458-5407CF75-00CB-4FC9-A616-C76ED5A33A87Q33624655-279DC0BD-04AF-4F03-BE36-40296E9D6015Q33718295-4E42B14B-0596-407B-8028-79EF9598E852Q33727000-8C50CCEC-9875-4797-B579-77F93BEC210BQ33735409-DD1968AB-C0D2-4AD1-AC46-B436E4A84015Q33746038-7A915C18-8145-4DAD-8FD1-64FD6847048AQ33777452-9E264A99-3DA0-49E7-9739-786329D9D93FQ33893567-4F456D81-6A84-4BCD-BE6F-8642A22D9887Q34737435-55FBD123-CE67-423B-B377-586508CD7957Q34764772-190656BD-8C88-4047-B0CD-114CF0D593F8Q35066862-4CA5A727-43A0-478A-9CE2-E35B6C70330BQ35117394-54C5633D-5CA0-4828-BF1E-C387B28EA413Q35124976-394E3FDF-826E-4BDB-BD1A-C65BB6991128Q35191379-748D6C18-E59E-40AB-B9C8-181B02366807Q35208637-1EDD7182-4F4C-445A-839A-19BE8DCE9B14Q35571249-9A70E222-7B10-4398-A9F6-39F0F08AB2B6Q35744435-DC26ECAF-997F-4A48-A21B-A99D6D4DCC1EQ35779480-5B71A05D-974B-4D64-B939-00D7773C34CDQ36100105-D26A5B8D-5E46-48ED-88B5-EF227190312DQ36117678-D6A5629C-320A-4AEC-9F5A-B11A7C616120Q36357419-298EB488-D779-4401-A78E-9AD8994819CDQ36565896-696FA692-50DA-4E18-A126-0D6DB1357EB5Q37026545-302724B5-0BEB-4F87-9370-52AA203F5755Q37142225-43F7AD72-58BC-4CD9-92E5-5643AB0F74D1Q37206124-65FF1D65-3769-4865-8182-4DF448884D5FQ37271507-C8ABAFC4-4D93-46EB-AFC7-B0321CC8DCF8Q37309142-B4E619AC-4A60-4804-B8F9-07F88F964A64Q37340339-322DC0F8-0D5C-4FED-91B3-8CE05E4EDDDCQ37386612-7BE9F629-3FCB-40C2-AA06-4CCB39111D58Q37559634-566D9A2E-289B-4146-BEE9-ABAB9C422556Q37618534-0E6E6CB3-3A12-45F2-AB60-0499244A7703Q37646785-1C489525-55DF-46C5-BCF9-A66F57B876E8Q38029324-35FBC451-6D25-4E8C-8DE2-F90D118EC731Q38128176-FCF9188F-AC2D-4F4B-8A33-7428749B5350
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Eradication therapy for Helicobacter pylori.
@en
type
label
Eradication therapy for Helicobacter pylori.
@en
prefLabel
Eradication therapy for Helicobacter pylori.
@en
P1433
P1476
Eradication therapy for Helicobacter pylori.
@en
P2093
Francis Megraud
Nimish Vakil
P304
P356
10.1053/J.GASTRO.2007.07.008
P407
P577
2007-09-01T00:00:00Z